



Cobicistat

Catalog No: tcsc0742

	7	

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1004316-88-4

Formula:

 $C_{40}H_{53}N_7O_5S_2$

Pathway:

Metabolic Enzyme/Protease

Target:

Cytochrome P450

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 29 mg/mL (37.37 mM)

Alternative Names:

GS-9350

Observed Molecular Weight:

776.02



Product Description

Cobicistat is a potent, and selective inhibitor of **cytochrome P450 3A (CYP3A)** enzymes with IC_{50} of 30-285 nM.

IC50 & Target: IC50: 30-285 nM (Cytochrome P450)[1]

In Vitro: Cobicistat (GS-9350) is a potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes as a pharmacoenhancer. GS-9350 inhibits CYP3A with IC_{50} spectrum from 30 nM to 285 nM. In contrast to ritonavir, GS-9350 is devoid of anti-HIV activity, with IC_{50} of > 30 μ M against HIV-1 protease and EC_{50} of > 30 μ M in MT-2 HIV infection assay, and is thus more suitable for use in boosting anti-HIV drugs without risking selection of potential drug-resistant HIV variants. GS-9350 shows reduced liability for drug interactions and may have potential improvements in tolerability over ritonavir^[1]. Cobicistat is a novel cytochrome P450 3A4 inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs. It lacks significant anti-HIV activity and is more selective than ritonavir in its enzyme inhibition^[2].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!